Shares of Gilead Sciences Inc. (NASDAQ:GILD) have earned an average rating of “Buy” from the thirty ratings firms that are currently covering the firm. Ten investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have given a strong buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $102.14.
GILD has been the topic of several analyst reports. Royal Bank Of Canada increased their target price on Gilead Sciences from $95.00 to $105.00 and gave the company an “outperform” rating in a research note on Monday, October 3rd. Jefferies Group cut their target price on Gilead Sciences from $93.00 to $91.00 and set a “hold” rating on the stock in a research note on Wednesday, August 31st. Zacks Investment Research raised Gilead Sciences from a “sell” rating to a “hold” rating in a research note on Monday, September 26th. Piper Jaffray Cos. reissued an “overweight” rating and issued a $108.00 target price on shares of Gilead Sciences in a research note on Wednesday, August 31st. Finally, Leerink Swann set a $112.00 target price on Gilead Sciences and gave the company a “buy” rating in a research note on Thursday, September 22nd.
Shares of Gilead Sciences (NASDAQ:GILD) opened at 72.75 on Friday. Gilead Sciences has a 52 week low of $72.21 and a 52 week high of $111.11. The company has a market cap of $96.01 billion, a PE ratio of 6.38 and a beta of 1.10. The company has a 50 day moving average price of $77.93 and a 200 day moving average price of $84.45.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.02 by $0.06. Gilead Sciences had a return on equity of 106.75% and a net margin of 50.50%. The business had revenue of $7.78 billion for the quarter, compared to analyst estimates of $7.80 billion. During the same quarter in the prior year, the firm posted $3.15 earnings per share. The firm’s revenue for the quarter was down 5.7% compared to the same quarter last year. On average, equities analysts expect that Gilead Sciences will post $11.76 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which was paid on Thursday, September 29th. Stockholders of record on Friday, September 16th were paid a $0.47 dividend. The ex-dividend date of this dividend was Wednesday, September 14th. This represents a $1.88 annualized dividend and a dividend yield of 2.58%. Gilead Sciences’s payout ratio is 16.56%.
In other news, EVP Gregg H. Alton sold 5,000 shares of Gilead Sciences stock in a transaction on Thursday, September 22nd. The stock was sold at an average price of $81.84, for a total value of $409,200.00. Following the transaction, the executive vice president now owns 132,964 shares in the company, valued at approximately $10,881,773.76. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider John C. Martin sold 100,000 shares of Gilead Sciences stock in a transaction on Monday, August 1st. The shares were sold at an average price of $80.50, for a total value of $8,050,000.00. Following the completion of the transaction, the insider now owns 4,119,727 shares in the company, valued at approximately $331,638,023.50. The disclosure for this sale can be found here. 1.40% of the stock is owned by insiders.
Several institutional investors have recently modified their holdings of the stock. Aperio Group LLC raised its position in shares of Gilead Sciences by 1.4% in the first quarter. Aperio Group LLC now owns 559,151 shares of the biopharmaceutical company’s stock valued at $51,364,000 after buying an additional 7,593 shares during the last quarter. Commonwealth Equity Services Inc raised its stake in shares of Gilead Sciences by 16.4% in the first quarter. Commonwealth Equity Services Inc now owns 309,628 shares of the biopharmaceutical company’s stock worth $28,442,000 after buying an additional 43,573 shares in the last quarter. Telemus Capital LLC raised its stake in shares of Gilead Sciences by 171.9% in the first quarter. Telemus Capital LLC now owns 59,934 shares of the biopharmaceutical company’s stock worth $5,506,000 after buying an additional 37,895 shares in the last quarter. Arvest Bank Trust Division raised its stake in shares of Gilead Sciences by 2.4% in the first quarter. Arvest Bank Trust Division now owns 244,185 shares of the biopharmaceutical company’s stock worth $22,431,000 after buying an additional 5,824 shares in the last quarter. Finally, Sii Investments Inc. WI raised its stake in shares of Gilead Sciences by 4.2% in the first quarter. Sii Investments Inc. WI now owns 40,057 shares of the biopharmaceutical company’s stock worth $3,679,000 after buying an additional 1,601 shares in the last quarter. Institutional investors own 77.93% of the company’s stock.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.